IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus‐/HCV‐coinfected patients

Due to the poor rate of response to hepatitis C virus (HCV) with pegylated interferon and ribavirin treatment in HCV/HIV coinfected patients, key factors for predicting failure would be useful. We performed a retrospective study on 291 patients on HCV treatment, who had early virological response (EVR) data. IL28B and IL28RA polymorphisms were performed using the GoldenGate® assay. Unfavourable genotypes at IL28B (rs12980275 AG/GG and rs8099917 GT/GG) and an unfavourable allele at IL28RA (rs10903035 G) were associated with early treatment failure. However, only the rs12980275 AG/GG genotype and rs10903035 G allele remained independently associated with early failure in the overall population (OR = 4.15 (95% CI = 1.64–10.54) and OR = 2.00 (95% CI = 1.19–3.36), respectively) as well as in GT1/4 patients (OR = 5.07 (95% CI = 1.81–14.22) and OR = 2.03 (95% CI = 1.13–3.66), respectively). Next, a decision tree showed early treatment failure increased from 37.1% to 65.5% when the unfavourable rs12980275 AG/GG and rs10903035 AG/GG genotypes and HCV‐RNA≥ 500.000 IU/mL were taken into account in GT1/4 patients. In contrast, the failure rate decreased from 37.1% to 11.9% when the favourable rs12980275 AA and rs10903035 AA genotypes were detected. The percentage of patients correctly classified was 78.4%, and AUROC was 0.802 ± 0.028. Regarding GT3 patients, the presence of the GCGCA haplotype (all unfavourable alleles) was associated with early treatment failure, while no association was observed for the IL28B polymorphisms. In conclusion, the IL28RA polymorphism was associated with early treatment failure independently of the IL28B SNPs. The combination of IL28B and IL28RA polymorphisms might be a valuable tool for predicting early treatment failure before starting HCV treatment.

[1]  X. Montalban,et al.  Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis , 2012, Journal of Neuroimmunology.

[2]  E. Poveda,et al.  Pharmacogenetics of hepatitis C. , 2012, The Journal of antimicrobial chemotherapy.

[3]  A. Lok,et al.  IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection , 2012, Journal of viral hepatitis.

[4]  B. Clotet,et al.  Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients , 2012, PloS one.

[5]  D. Levy,et al.  Induction and function of type I and III interferon in response to viral infection. , 2011, Current opinion in virology.

[6]  Jun Li,et al.  Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. , 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[7]  P. Desmond,et al.  Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. , 2011, Clinics in liver disease.

[8]  J. Macías,et al.  Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients , 2011, AIDS.

[9]  C. Tural,et al.  The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients , 2011, AIDS.

[10]  C. Datz,et al.  Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  M. Sulkowski.  Exploring the possibility of an interferon-free treatment regimen for hepatitis C virus infection. , 2011, Gastroenterology & hepatology.

[12]  Julia E. Vogt,et al.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. , 2011, Gastroenterology.

[13]  K. Shianna,et al.  Hepatitis C pharmacogenetics: State of the art in 2010 , 2011, Hepatology.

[14]  J. Benito,et al.  Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  B. Clotet,et al.  IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients , 2010, PloS one.

[16]  Matti Pirinen,et al.  A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 , 2010, Nature Genetics.

[17]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[18]  Shaoheng He,et al.  Integrative genomic analyses on IL28RA, the common receptor of interferon-λ1, -λ2 and -λ3 , 2010 .

[19]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[20]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[21]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[22]  R. Chung,et al.  Coinfection with HIV-1 and HCV--a one-two punch. , 2009, Gastroenterology.

[23]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[24]  B. Clotet,et al.  Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV–Hiv-Coinfected Patients , 2008, Antiviral therapy.

[25]  V. Soriano,et al.  Management of chronic hepatitis C virus infection in HIV-infected patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[27]  V. Soriano,et al.  Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. , 2007, AIDS.

[28]  A. Nielsen,et al.  Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein Kinases , 2007, Journal of Virology.

[29]  J. Gatell,et al.  Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin , 2007, Journal of acquired immune deficiency syndromes.

[30]  J. R. Arribas,et al.  Estudio multicéntrico sobre prevalencia de las coinfecciones por virus de hepatitis, indicación de tratamiento de hepatitis crónica C y necesidad de trasplante hepático en pacientes infectados por el VIH en España. Estudio GESIDA 29/02-FIPSE 12185/01 , 2005 .

[31]  G. Abecasis,et al.  A note on exact tests of Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[32]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[33]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[34]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[35]  J. Torre-Cisneros,et al.  Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. , 2012, The Journal of antimicrobial chemotherapy.